The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative-Reference-Cited by-同舟云学术

The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4- positive T-cells that are PD-1-negative

Published:2019-10-10 Issue: Volume: Page:
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Patel Sanjay S.¹,Weirather Jason L.²^ORCID,Lipschitz Mikel³,Lako Ana²,Chen Pei-Hsuan⁴,Griffin Gabriel K.⁴,Armand Philippe²,Shipp Margaret A.²^ORCID,Rodig Scott J.⁴

Affiliation:

1. Weill Cornell Medical College, New York, New York, United States

2. Dana-Farber Cancer Institute, Boston, Massachusetts, United States

3. DFCI, Boston, Massachusetts, United States

4. Brigham and Women's Hospital, Boston, Massachusetts, United States

Abstract

Key Points CTLA-4 is enriched in the microenvironmental niche in cHL, and identifies a T-cell population largely distinct from PD-1 CD86, the natural ligand for CTLA-4, is enriched in the niche and expressed on HRS cells and a subset of TAMs that also express PD-L1

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2019002206/1223907/blood.2019002206.pdf

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single‐cell RNA sequencing of pediatric Hodgkin lymphoma to study the inhibition of T cell subtypes;HemaSphere;2024-09

2. Intra‐tumoral and peripheral blood TIGIT and PD‐1 as immune biomarkers in nodular lymphocyte predominant Hodgkin lymphoma;American Journal of Hematology;2024-08-17

3. Expression and prognostic impact of CD73 in classical Hodgkin lymphoma;2024-06-17

4. Human leukocyte antigen (HLA) class I expression on Hodgkin–Reed–Sternberg cells is an EBV‐independent major determinant of microenvironment composition in classic Hodgkin lymphoma;HemaSphere;2024-06

5. Emerging immunotherapies in the Hodgkin lymphoma armamentarium;Expert Opinion on Emerging Drugs;2024-05-06